We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.53%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.06B
AUM Growth
+$54.1M
Cap. Flow
-$57.6M
Cap. Flow %
-5.46%
Top 10 Hldgs %
34.88%
Holding
95
New
10
Increased
31
Reduced
41
Closed
11

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$29.7M
2
ELV icon
Elevance Health
ELV
+$28.1M
3
BDX icon
Becton Dickinson
BDX
+$27.8M
4
PEN icon
Penumbra
PEN
+$10.8M
5
MRK icon
Merck
MRK
+$8.75M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$22.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$18.7M
3
HUM icon
Humana
HUM
+$17.9M
4
LLY icon
Eli Lilly
LLY
+$17M
5
PFE icon
Pfizer
PFE
+$16.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Industrials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
1
Cigna
CI
$73.7B
$49.8M 4.72%
137,171
+90,171
+192% +$29.7M
LLY icon
2
Eli Lilly
LLY
$1.02T
$42.1M 3.99%
54,175
-23,830
-31% -$17M
THC icon
3
Tenet Healthcare
THC
$20.5B
$39.9M 3.79%
380,000
+28,370
+8% +$2.55M
BSX icon
4
Boston Scientific
BSX
$69.5B
$39.9M 3.78%
582,000
-168,000
-22% -$10.8M
ELV icon
5
Elevance Health
ELV
$81.5B
$36M 3.42%
69,500
+56,500
+435% +$28.1M
ABBV icon
6
AbbVie
ABBV
$443B
$34.5M 3.27%
189,500
+22,500
+13% +$3.88M
HCA icon
7
HCA Healthcare
HCA
$87.2B
$33.4M 3.16%
100,000
-9,000
-8% -$2.75M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$78.5B
$33M 3.13%
34,300
-4,700
-12% -$4.47M
COO icon
9
Cooper Companies
COO
$14.1B
$30.5M 2.89%
301,000
+67,000
+29% +$6.48M
MRK icon
10
Merck
MRK
$322B
$28.8M 2.73%
218,500
+71,000
+48% +$8.75M
BDX icon
11
Becton Dickinson
BDX
$45.6B
$28.7M 2.72%
+116,000
New +$27.8M
MDT icon
12
Medtronic
MDT
$109B
$28.3M 2.68%
325,000
-266,000
-45% -$22.7M
OSCR icon
13
Oscar Health
OSCR
$9.41B
$25.2M 2.38%
1,691,522
+499,468
+42% +$6.84M
PRCT icon
14
Procept Biorobotics
PRCT
$1.06B
$24.1M 2.28%
487,063
+177,063
+57% +$8.43M
MCK icon
15
McKesson
MCK
$100B
$23.6M 2.24%
44,000
-2,000
-4% -$1.02M
VRTX icon
16
Vertex Pharmaceuticals
VRTX
$121B
$23.6M 2.24%
56,500
-38,500
-41% -$16.3M
NTRA icon
17
Natera
NTRA
$38.3B
$22M 2.08%
240,000
-5,000
-2% -$376K
ABT icon
18
Abbott
ABT
$183B
$21M 1.99%
185,000
-20,000
-10% -$2.29M
SWAV
19
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$20.8M 1.98%
64,000
-76,000
-54% -$18.7M
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$11.6B
$20.7M 1.97%
237,500
-45,000
-16% -$4.03M
ISRG icon
21
Intuitive Surgical
ISRG
$127B
$20.2M 1.91%
50,500
-13,000
-20% -$4.91M
UNH icon
22
UnitedHealth
UNH
$376B
$20M 1.9%
40,500
-13,500
-25% -$6.86M
DXCM icon
23
DexCom
DXCM
$31.5B
$19.2M 1.82%
138,500
+28,500
+26% +$3.58M
JAZZ icon
24
Jazz Pharmaceuticals
JAZZ
$15.9B
$17.7M 1.67%
146,729
+23,095
+19% +$2.83M
RPRX icon
25
Royalty Pharma
RPRX
$25.9B
$16.5M 1.57%
544,697
+115,000
+27% +$3.39M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rhenman & Partners Asset Management held 95 positions worth $1.06B, up 5.4% from $1B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $57.6M in Q1 2024, closing 11 positions and reducing 41 holdings. Its most notable exit was Humana, an estimated $17.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Becton Dickinson worth $28.7M.

  • Rhenman & Partners Asset Management's largest Q1 2024 buy was Becton Dickinson: 116,000 shares worth $28.7M.
  • Rhenman & Partners Asset Management added most to Cigna in Q1 2024, an estimated $29.7M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2024 reduction was Medtronic, cutting an estimated $22.7M.
  • Rhenman & Partners Asset Management fully exited Humana in Q1 2024, selling an estimated $17.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1.06B portfolio in Q1 2024.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 11 in Q1 2024.
  • Rhenman & Partners Asset Management's portfolio value rose 5.4% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2024, filed 14 May 2024.